| Yesterday | ||||
Credit Suisse analyst… Credit Suisse analyst Trung Huynh lowered the firm's price target on Roche to CHF 350 from CHF 370 and keeps a Neutral rating on the shares. | ||||
| Wednesday | ||||
Sorrento Therapeutics… Sorrento Therapeutics announced the appointment of Tammy Reilly, to Sorrento's board of directors. Ms. Reilly is the managing partner of a life sciences advisory company, TRDx LLC, an independent firm that she founded 15 years ago to advise life science companies on life cycle management and business development solutions, which includes advice on mergers and acquisitions and strategic and capital markets transactions. Reilly also served in various roles at Roche Laboratories for over 14 years, including sales and marketing leadership positions and most recently in 2005 as Executive Vice President for Oncology and Dermatology at Roche. | ||||
| Monday | ||||
Virtual ESG Event: Access… Virtual ESG Event: Access to Healthcare to be held on May 16 at 9 am. Webcast Link | ||||
Virtual ESG Event: Access… Virtual ESG Event: Access to Healthcare to be held on May 16 at 9 am. Webcast Link | ||||
Virtual ESG Event: Access… Virtual ESG Event: Access to Healthcare to be held on May 16 at 9 am. Webcast Link | ||||
| Over a week ago | ||||
Jefferies analyst Peter… Jefferies analyst Peter Welford downgraded Roche (RHHBY) to Hold from Buy with a price target of CHF 360, down from CHF 430. The analyst says oncology pipelines setbacks for tiragolumab and giredestrant has "many growing wary" into the gantenerumab binary Alzheimer's readout in Q4. He prefers GlaxoSmithKline (GSK) in the near term on the company's consumer spin value creation as well as Novartis (NVS) for Swiss yield and value. | ||||
Morgan Stanley analyst… Morgan Stanley analyst Mark Purcell lowered the firm's price target on Roche to CHF 370 from CHF 395 and keeps an Equal Weight rating on the shares. | ||||
Piper Sandler analyst… Piper Sandler analyst Christopher Raymond lowered the firm's price target on iTeos Therapeutics (ITOS) to $34 from $42 and keeps an Overweight rating on the shares. The anlayst sees a higher risk profile for iTeos after Roche's (RHHBY) anti-TIGIT antibody tiragolumab failed to show a benefit in non-small cell lung cancer. Given the direct read-through to EOS-448, investors must acknowledge this "much anticipated" new immuno-oncology class now has more risk, Raymond tells investors in a research note. On the "bright side," investors can take comfort in iTeos management's foresight in partnering the molecule to GSK for $625M up front providing cash runway into 2026, adds the analyst. | ||||
Wedbush analyst Robert… Wedbush analyst Robert Driscoll lowered the firm's price target on Arcus Biosciences (RCUS) to $42 from $67 and keeps an Outperform rating on the shares. The analyst notes Roche (RHHBY) reported that the Phase 3 SKYSCRAPER-01 study failed to meet the co-primary endpoint of PFS, which he believes casts a shadow on Arcus' mNSCLC programs given the similarity of study designs. | ||||
Deutsche Bank analyst… Deutsche Bank analyst Emmanuel Papadakis downgraded Roche to Hold from Buy with a CHF 350 price target after the Phase III SKYSCRAPER-01 study failed in lung cancer. "It is indeed back to the drawing board," Papadakis tells investors in a research note. | ||||
